Clinical Trials Logo

Parainfluenza clinical trials

View clinical trials related to Parainfluenza.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02984280 Completed - Clinical trials for Cardiovascular Diseases

Specific Respiratory Infections as Triggers of Acute Medical Events

Start date: September 2016
Phase: N/A
Study type: Observational

This study will investigate whether there is a population-level association between circulating respiratory viruses and NHS hospital admissions for acute vascular events using data from national infection surveillance and Hospital Episode Statistics.

NCT ID: NCT01924793 Completed - Parainfluenza Clinical Trials

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

PIV
Start date: August 2013
Phase: Phase 2
Study type: Interventional

This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.

NCT ID: NCT01644877 Completed - Parainfluenza Clinical Trials

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

DAS181-2-05
Start date: March 2014
Phase: Phase 2
Study type: Interventional

This protocol will seek to enroll immunocompromised patients who are on supplemental oxygen and diagnosed with a parainfluenza infection.

NCT ID: NCT00641017 Completed - Virus Diseases Clinical Trials

Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

Start date: March 2008
Phase: Phase 1
Study type: Interventional

Human Parainfluenza Virus Type 1 (HPIV1) is a leading cause of viral respiratory infections in children, the elderly, and those with compromised immune systems. HPIV1 is also the leading cause of viral croup in children under 6 years old. The purpose of this study is to determine the safety of and immune response to a HPIV1 vaccine, rHPIVI1 84/del170/942A, in 2 groups of adults and then in children who have been previously exposed to HPIV1. Once the safety of this vaccine has been established in these groups, an additional 2 groups of infants and children who have not been previously exposed to HPIV1 will be vaccinated. Naïve infants and children are the most vulnerable to naturally circulating HPIV1 and are the target population of this vaccine.